论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)患者血清干细胞核心转录因子性别决定区Y框蛋白2自身抗体(Sox2-Ab)水平及其临床意义。方法 ELISA法检测38例NSCLC患者(肺癌组)和30名健康体检者(对照组)血清Sox2-Ab的表达,分析其与NSCLC临床病理特征的相关性。结果肺癌组Sox2-Ab的表达水平高于对照组[(9.18±1.25)ng/ml vs.(8.29±0.71)ng/ml](P<0.05)。血清Sox2-Ab水平升高与NSCLC临床分期、远处转移相关,与性别、年龄、肿瘤大小、病理类型及组织分化程度无关。结论 NSCLC患者血清Sox2-Ab水平升高;Sox2-Ab可能成为预测肺癌发生、发展的生物学标志物。
Objective To investigate the level of Sox2-Ab in the sex determining region of the serum CSF core transcription factor in patients with non-small cell lung cancer (NSCLC) and its clinical significance. Methods Serum levels of Sox2-Ab in 38 patients with NSCLC (lung cancer group) and 30 healthy controls (control group) were detected by ELISA. The correlation between the expression of Sox2-Ab and the clinicopathological features of NSCLC was analyzed. Results The expression level of Sox2-Ab in lung cancer group was significantly higher than that in the control group [(9.18 ± 1.25) ng / ml vs. (8.29 ± 0.71) ng / ml] (P <0.05). Serum levels of Sox2-Ab were correlated with clinical stage and distant metastasis of NSCLC, but not with gender, age, tumor size, pathological type and degree of tissue differentiation. Conclusion Serum Sox2-Ab levels are elevated in patients with NSCLC. Sox2-Ab may be a biomarker for predicting the occurrence and development of lung cancer.